Molnupiravir
Revision as of 20:28, 18 January 2022 by Rossdonaldson1 (talk | contribs) (Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: *Common Trade Names: ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== ===Drug pregnan...")
Administration
- Type:
- Dosage Forms:
- Routes of Administration:
- Common Trade Names:
Adult Dosing
Pediatric Dosing
Special Populations
Pregnancy Rating
Lactation risk
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
Comments
- Molnupiravir (Merck)
- Ages 18 and older only, mild to moderate disease only
- Within 5 days of symptom onset
- 800 mg q12hr x 5d
- Phase 3 trial showed 30% reduction in risk of hospitalization or death
- Avoid in pregnant or young patients given concern for mutagenicity